Arsenic neurotoxicity - A review

被引:250
作者
Vahidnia, A. [2 ]
Van der Voet, G. B. [3 ]
de Wolf, F. A. [1 ]
机构
[1] Leiden Univ, Med Ctr, Chair Clin & Forens Toxicol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands
[3] Armed Forces Inst Pathol, Dept Environm & Toxicol Pathol, Washington, DC 20306 USA
关键词
arsenic; metabolism; mechanism; neurotoxicity;
D O I
10.1177/0960327107084539
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Arsenic (As) is one of the oldest poisons known to men. Its applications throughout history are wide and varied: murder, make-up, paint and even as a pesticide. Chronic As toxicity is a global environmental health problem, affecting millions of people in the USA and Germany to Bangladesh and Taiwan. Worldwide, As is released into the environment by smelting of various metals, combustion of fossil fuels, as herbicides and fungicides in agricultural products. The drinking water in many countries, which is tapped from natural geological resources, is also contaminated as a result of the high level of As in groundwater. The environmental fate of As is contamination of surface and groundwater with a contaminant level higher than 10 particle per billion (ppb) as set by World Health Organization (WHO). Arsenic exists in both organic and inorganic species and either form can also exist in a trivalent or pentavalent oxidation state. Longterm health effects of exposure to these As metabolites are severe and highly variable: skin and lung cancer, neurological effects, hypertension and cardiovascular diseases. Neurological effects of As may develop within a few hours after ingestion, but usually are seen in 2-8 weeks after exposure. It is usually a symmetrical sensorimotor neuropathy, often resembling the Guillain-Barre syndrome. The predominant clinical features of neuropathy are paresthesias, numbness and pain, particularly in the soles of the feet. Electrophysiological studies performed on patients with As neuropathy have revealed a reduced nerve conduction velocity, typical of those seen in axonal degeneration. Most of the adverse effects of As, are caused by inactivated enzymes in the cellular energy pathway, whereby As reacts with the thiol groups of proteins and enzymes and inhibits their catalytic activity. Furthermore, As-induced neurotoxicity, like many other neurodegenerative diseases, causes changes in cytoskeletal protein composition and hyperphosphorylation. These changes may lead to disorganization of the cytoskeletal framework, which is a potential mechanism of As-induced neurotoxicity.
引用
收藏
页码:823 / 832
页数:10
相关论文
共 87 条
  • [71] STEINGASS A, 1947, COMPREHENSIVE PERSIO
  • [72] Slow recovery from severe inorganic arsenic poisoning despite treatment with DMSA (2.3-dimercaptosuccinic acid)
    Stenehjem, Aud-E.
    Vahter, Marie
    Nermell, Barbro
    Aasen, Jorulf
    Lierhagen, Syverin
    Morland, Jorg
    Jacobsen, Dag
    [J]. CLINICAL TOXICOLOGY, 2007, 45 (04) : 424 - 428
  • [73] Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells
    Styblo, M
    Del Razo, LM
    Vega, L
    Germolec, DR
    LeCluyse, EL
    Hamilton, GA
    Reed, W
    Wang, C
    Cullen, WR
    Thomas, DJ
    [J]. ARCHIVES OF TOXICOLOGY, 2000, 74 (06) : 289 - 299
  • [74] EFFECT OF AS2O3 ON GLUCONEOGENESIS
    SZINICZ, L
    FORTH, W
    [J]. ARCHIVES OF TOXICOLOGY, 1988, 61 (06) : 444 - 449
  • [75] Treatment of relapsed or refractory acute promyelocytic leukemia
    Tallman, Martin S.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (01) : 57 - 65
  • [76] Tseng HP, 2006, J HEALTH POPUL NUTR, V24, P182
  • [77] Arsenic-induced toxicity: effect on protein composition in sciatic nerve
    Vahidnia, A.
    Romijn, F.
    Tiller, M.
    van der Voet, G. B.
    de Wolff, F. A.
    [J]. HUMAN & EXPERIMENTAL TOXICOLOGY, 2006, 25 (11) : 667 - 674
  • [78] Arsenic metabolites affect expression of the neurofilament and tau genes: An in-vitro study into the mechanism of arsenic neurotoxicity
    Vahidnia, A.
    van der Straaten, R. J. H. M.
    Romijn, F.
    Van Pelt, J.
    van der Voet, G. B.
    de Wolff, F. A.
    [J]. TOXICOLOGY IN VITRO, 2007, 21 (06) : 1104 - 1112
  • [79] Role of metabolism in arsenic toxicity
    Vahter, M
    Concha, G
    [J]. PHARMACOLOGY & TOXICOLOGY, 2001, 89 (01): : 1 - 5
  • [80] VANDERVOET GB, 1991, PROG HISTOCHEM CYTOC, V23, P235